Gene delivery from
the vitreous to the
outer retina.

An engineered capsid with demonstrated photoreceptor and retinal pigment epithelium transduction following intravitreal delivery.

Scientific evidence

Demonstrated biological activity.

Published retinal delivery and functional-payload studies in animal models [1]

Photoreceptors and RPE

Robust outer-retinal transgene expression following intravitreal administration.

Functional payload delivery

Nrf2 expression reduced oxidative-damage staining in retinal tissue.

Nuc1 enhancement

Co-administration with Nuc1 enhanced AAV-IKV-mediated retinal expression.

Platform application

One delivery platform. Multiple ocular applications.

AAV-IKV connects capsid engineering with therapeutic gene expression in retinal tissue. Separate intracameral work demonstrated corneal transgene expression in a nonhuman-primate pilot study [2], complementing the retinal delivery evidence.

Platform: Engineered AAV-IKV capsid
Retinal delivery: Intravitreal
Additional ocular evidence: Primate corneal expression · intracameral

Supporting sources

[1] Kumar and colleagues. IOVS. 2024;65(10):30. Retinal-penetrating AAV. PMID: 39172462. ↗

[2] Rao and colleagues. Scientific Reports. 2025;15:8051. DOI: 10.1038/s41598-025-92273-5. ↗

Strategic partnerships

Start with the science.

Technology collaborations, strategic partnerships and investment discussions.

Contact Visiogene